FDA Approves Takeda’s Anti-Hypertensive Drug

by Kathy Jones on  February 26, 2011 at 7:42 PM Drug News   - G J E 4
The US Food and Drug Administration has given its approval for Takeda Pharmaceutical to market its hypertension drug in the country.

To be sold under the name of Edarbi, the pill is a derivative of azilsartan medoxomil which is an angiotensin II receptor blocker (ARB).
 FDA Approves Takeda’s Anti-Hypertensive Drug
FDA Approves Takeda’s Anti-Hypertensive Drug

It helps in blocking out the angiotensin II which is responsible for the constricting of the blood vessels and thereby reduces the blood pressure.

Expressing his delight at receiving the approval, the CEO of Takeda Pharmaceuticals North America, Shinji Honda said, "Through the discovery, development and commercialization of new medicines, Takeda is committed to bringing therapies like EDARBI to market. EDARBI is an important new treatment option for patients with hypertension and the health care professionals who treat them".

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like